BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 17386267)

  • 1. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms.
    Brognard J; Sierecki E; Gao T; Newton AC
    Mol Cell; 2007 Mar; 25(6):917-31. PubMed ID: 17386267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The phosphatase PHLPP controls the cellular levels of protein kinase C.
    Gao T; Brognard J; Newton AC
    J Biol Chem; 2008 Mar; 283(10):6300-11. PubMed ID: 18162466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PHLiPPing the switch on Akt and protein kinase C signaling.
    Brognard J; Newton AC
    Trends Endocrinol Metab; 2008 Aug; 19(6):223-30. PubMed ID: 18511290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice.
    Li X; Stevens PD; Liu J; Yang H; Wang W; Wang C; Zeng Z; Schmidt MD; Yang M; Lee EY; Gao T
    Gastroenterology; 2014 May; 146(5):1301-12.e1-10. PubMed ID: 24530606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PHLPP isoforms differentially regulate Akt isoforms and AS160 affecting neuronal insulin signaling and insulin resistance via Scribble.
    Sharma M; Dey CS
    Cell Commun Signal; 2022 Nov; 20(1):179. PubMed ID: 36376971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PHLPPing through history: a decade in the life of PHLPP phosphatases.
    Grzechnik AT; Newton AC
    Biochem Soc Trans; 2016 Dec; 44(6):1675-1682. PubMed ID: 27913677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diacylglycerol kinase δ modulates Akt phosphorylation through pleckstrin homology domain leucine-rich repeat protein phosphatase 2 (PHLPP2).
    Crotty TM; Nakano T; Stafforini DM; Topham MK
    J Biol Chem; 2013 Jan; 288(3):1439-47. PubMed ID: 23184957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation.
    Nitsche C; Edderkaoui M; Moore RM; Eibl G; Kasahara N; Treger J; Grippo PJ; Mayerle J; Lerch MM; Gukovskaya AS
    Gastroenterology; 2012 Feb; 142(2):377-87.e1-5. PubMed ID: 22044669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleckstrin Homology (PH) Domain Leucine-rich Repeat Protein Phosphatase Controls Cell Polarity by Negatively Regulating the Activity of Atypical Protein Kinase C.
    Xiong X; Li X; Wen YA; Gao T
    J Biol Chem; 2016 Nov; 291(48):25167-25178. PubMed ID: 27760826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological inhibition of pleckstrin homology domain leucine-rich repeat protein phosphatase is neuroprotective: differential effects on astrocytes.
    Jackson TC; Verrier JD; Drabek T; Janesko-Feldman K; Gillespie DG; Uray T; Dezfulian C; Clark RS; Bayir H; Jackson EK; Kochanek PM
    J Pharmacol Exp Ther; 2013 Nov; 347(2):516-28. PubMed ID: 24023368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between polycomb-group protein BMI-1 and phosphatases regulating AKT phosphorylation level in endometrial cancer.
    Zaczek A; Jóźwiak P; Ciesielski P; Forma E; Wójcik-Krowiranda K; Cwonda Ł; Bieńkiewicz A; Bryś M; Krześlak A
    J Cell Mol Med; 2020 Jan; 24(2):1300-1310. PubMed ID: 31863623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical characterization of the phosphatase domain of the tumor suppressor PH domain leucine-rich repeat protein phosphatase.
    Sierecki E; Newton AC
    Biochemistry; 2014 Jun; 53(24):3971-81. PubMed ID: 24892992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of PH-domain leucine-rich protein phosphatase 2 (PHLPP2) by agonist stimulation in cardiac myocytes expressing adenylyl cyclase type 6.
    Gao MH; Miyanohara A; Feramisco JR; Tang T
    Biochem Biophys Res Commun; 2009 Jun; 384(2):193-8. PubMed ID: 19450723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Turning off AKT: PHLPP as a drug target.
    Newton AC; Trotman LC
    Annu Rev Pharmacol Toxicol; 2014; 54():537-58. PubMed ID: 24392697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the PHLPPside: Emerging roles of PHLPP phosphatases in the heart.
    Lemoine KA; Fassas JM; Ohannesian SH; Purcell NH
    Cell Signal; 2021 Oct; 86():110097. PubMed ID: 34320369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth.
    Liu J; Stevens PD; Li X; Schmidt MD; Gao T
    Mol Cell Biol; 2011 Dec; 31(24):4917-27. PubMed ID: 21986499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis.
    Liu J; Weiss HL; Rychahou P; Jackson LN; Evers BM; Gao T
    Oncogene; 2009 Feb; 28(7):994-1004. PubMed ID: 19079341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Berberine induced modulation of PHLPP2-Akt-MST1 kinase signaling is coupled with mitochondrial impairment and hepatoma cell death.
    Saxena S; Shukla S; Kakkar P
    Toxicol Appl Pharmacol; 2018 May; 347():92-103. PubMed ID: 29626488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of small molecule inhibitors of the PH domain leucine-rich repeat protein phosphatase (PHLPP) by chemical and virtual screening.
    Sierecki E; Sinko W; McCammon JA; Newton AC
    J Med Chem; 2010 Oct; 53(19):6899-911. PubMed ID: 20836557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth.
    Gao T; Furnari F; Newton AC
    Mol Cell; 2005 Apr; 18(1):13-24. PubMed ID: 15808505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.